IFN Regulatory Factor 2 Inhibits Expression of Glycolytic Genes and Lipopolysaccharide-Induced Proinflammatory Responses in Macrophages.
IFN Regulatory Factor 2 Inhibits Expression of Glycolytic Genes and Lipopolysaccharide-Induced Proinflammatory Responses in Macrophages.
复制标题
DOI:
10.4049/jimmunol.1701571
复制
发表时间:
2018-05-01
期刊:
影响因子:
--
通讯作者:
Liu G
中科院分区:
文献类型:
--
作者:
Cui H;Banerjee S;Guo S;Xie N;Liu G
Rapid initiation and timely resolution of inflammatory response in macrophages are synergistic events that are known to be equally critical to optimal host defense against pathogen infections. However, the regulation of these processes, in particular by specific cellular metabolic program, has not been well understood. In this study, we found that interferon regulatory factor 2 (IRF2) underwent an early degradation in a proteasome-mediated pathway in LPS treated mouse macrophages, followed by a later recovery of the expression via transactivation. We showed that IRF2 was anti-inflammatory in that knockdown of this protein promoted LPS induced pro-inflammatory mediators. Mechanistically, while IRF2 apparently did not target the proximal cytoplasmic signaling events upon LPS engagements, it inhibited HIF-1α dependent expression of glycolytic genes and thereby cellular glycolysis, sequential events necessary for the IRF2 anti-inflammatory activity. We found that macrophages in endotoxin tolerant state demonstrated deficiency in LPS augmented glycolysis, which was likely caused by failed downregulation of IRF2 and the ensuing upregulation of the glycolytic genes in these cells. In contrast to observations with LPS, knockdown of IRF2 decreased IL-4 induced macrophage alternative activation. The pro-IL-4 activity of IRF2 was dependent on KLF4, a key mediator of the alternative activation, which was transcriptionally induced by IRF2. In conclusion, our data suggest that IRF2 is an important regulator of the pro-inflammatory response in macrophages by controlling HIF-1α dependent glycolytic gene expression and glycolysis. This study also indicates IRF2 as a novel therapeutic target to treat inflammatory disorders associated with dysregulations of macrophage activations.
登录
查看更多内容
影响因子:
30.5
作者:
通讯作者:
--
DOI:
10.4049/jimmunol.1202496
发表时间:
2013-06-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Banerjee S;Xie N;Cui H;Tan Z;Yang S;Icyuz M;Abraham E;Liu G
通讯作者:
Liu G
影响因子:
64.5
作者:
Chang CH;Curtis JD;Maggi LB Jr;Faubert B;Villarino AV;O'Sullivan D;Huang SC;van der Windt GJ;Blagih J;Qiu J;Weber JD;Pearce EJ;Jones RG;Pearce EL
通讯作者:
Pearce EL
影响因子:
32.4
作者:
Hida, S;Ogasawara, K;Taniguchi, T
通讯作者:
Taniguchi, T
影响因子:
4.8
作者:
Liu, Gang;Park, Young-Jun;Abraham, Edward
通讯作者:
Abraham, Edward